The industry is on a strong growth trajectory, with experts predicting notable achievements over the next decade. Forecasts ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

Microba Life Sciences (ASX:MAP), which has technology for measuring the gut microbiome, has a strategic partnership deal with ...

A team of scientists has developed a new AI-based foundation model that can give insights into disease-causing mutations and ...

Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that ...

Agencies have always strived to build trust with their pharma clients, but that task is becoming more arduous as AI takes center stage.